Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ACTRIMS 2024 | MOVING-MS: using a multidimensional monitoring platform to inform clinical decision making in MS

Ferhan Qureshi, SVP – Biomarker R&D, Octave Bioscience, Menlo Park, CA, discusses the MOVING-MS study, in which the Octave precision care solution was used to monitor patients with relapsing/remitting multiple sclerosis (RRMS). This system uses a multifaceted approach to characterize the biological, imaging, and clinical trajectories of people with MS, aiming to better inform clinical decision making. In a series of patients enrolled in MOVING-MS, use of the precision care tool was able to capture clinically actionable events in between clinic visits, informing treatment course modification or continuation. Additionally, disease activity scores, calculated based on an extensive protein biomarker panel, were sensitive to symptom change and treatment within a short time interval. Dr Qureshi also mentions an ongoing assessment of physician satisfaction scores and healthcare utilization costs associated with the Octave platform within MOVING-MS. This interview took place during the annual ACTRIMS Forum 2024.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Ferhan Qureshi is an employee of Octave Bioscience.